Yuyu Pharma attendance at European Pharmaceutical Conference
Friday, November 04, 2022
Yuyu Pharma's CEO, Robert Yu, has been actively participating in biopharmaceutical conferences, specifically BIO-Europe in Leipzig and CPHI in Frankfurt, held in Germany. The primary objective of his attendance is to explore possibilities for expanding Yuyu Pharma into international markets, particularly in Europe.
During his presence at BIO-Europe and CPHI, Robert Yu has been diligently engaging with contract research organizations, Key Opinion Leaders, and potential clinical sites. This focused effort aims to prepare for upcoming clinical trials of Yuyu's dry eye drug, YP-P10, and androgenetic alopecia drug, DUT, in the United States and Europe. Yuyu Pharma is currently in the Phase 2 clinical trial stage for YP-P10, being conducted at seven sites with 240 patients in the United States.
In addition to these activities, Robert Yu intends to hold meetings with global pharmaceutical companies to explore potential collaborations. He also plans to connect with European officials regarding regulatory affairs and drug registration matters. Robert Yu acknowledges that attending these conferences provides a valuable opportunity to introduce Yuyu Pharma and its portfolio of drug discovery programs in development. The company has received positive feedback regarding its new drug pipeline, and they hope this will translate into commercial success in the future.
